Drugs & Aging

, Volume 32, Issue 12, pp 1009–1018 | Cite as

The Effect of Melatonin on Benzodiazepine Discontinuation and Sleep Quality in Adults Attempting to Discontinue Benzodiazepines: A Systematic Review and Meta-Analysis

  • Angela Wright
  • Jacqueline Diebold
  • Jaskiran Otal
  • Carly Stoneman
  • Jonathan Wong
  • Christine Wallace
  • Mark Duffett
Systematic Review

Abstract

Background

Abrupt discontinuation of benzodiazepines often results in side effects including anxiety and insomnia, which can be barriers to discontinuation among long-term users. Melatonin improves the onset, duration, and quality of sleep. By preventing insomnia in those attempting to discontinue benzodiazepines, melatonin may facilitate benzodiazepine discontinuation.

Objectives

The primary objective was to determine the effect of melatonin compared with placebo on benzodiazepine discontinuation in adults attempting to discontinue benzodiazepines. The secondary objective was to determine the effect of melatonin on sleep quality in this population.

Methods

We searched PubMed, MEDLINE, EMBASE, PsychINFO, and ClinicalTrials.gov from inception to November 2014. We included randomized controlled trials published in English comparing melatonin with placebo that reported benzodiazepine discontinuation or sleep quality. Two reviewers independently screened trials, extracted data, and assessed the risk of bias.

Results

We included six trials randomizing 322 participants. The mean age of participants was approximately 64 years. The trials used varied tapering strategies to discontinue benzodiazepines over 4–10 weeks while using melatonin. Melatonin had no effect on the odds of successfully discontinuing benzodiazepines (odds ratio 0.72, 95 % confidence interval 0.21–2.41, p = 0.59). There was important heterogeneity among the trials (I2 = 76 %). The effect of melatonin on sleep quality was inconsistent.

Conclusions

Melatonin had no effect on benzodiazepine discontinuation while the effect of melatonin on sleep quality was inconsistent. We cannot rule out a role of melatonin in improving benzodiazepine discontinuation or sleep quality owing to imprecise effect estimates. Larger, well-designed, and reported randomized controlled trials may provide more valid and precise estimates of the effect of melatonin on these outcomes.

References

  1. 1.
    National Guideline Clearinghouse (NGC). Guideline summary: clinical practice guidelines for the management of patients with insomnia in primary care. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ) [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
  2. 2.
    National Guideline Clearinghouse (NGC). Guideline summary: clinical guideline for the treatment of primary insomnia in middle-aged and older adults. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ) [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
  3. 3.
    National Guideline Clearinghouse (NGC). Guideline summary: generalised anxiety disorder and panic disorder (with or without agoraphobia) in adult. Management in primary, secondary and community care. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); [cited 12 Nov 2014]. Available from: http://www.guideline.gov. Accessed 24 Oct 2015.
  4. 4.
    Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13:919–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Ballokova A, Peel NM, Fialova D, Scott IA, Gray LC, Hubbard RE. Use of benzodiazepines and association with falls in older people admitted to hospital: a prospective cohort study. Drugs Aging. 2014;31:299–310.CrossRefPubMedGoogle Scholar
  6. 6.
    Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89:595–601.CrossRefPubMedGoogle Scholar
  7. 7.
    Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case–control study. BMJ. 2014. doi:10.1136/bmj.g5205.
  8. 8.
    Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues, JF, Peres K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012. doi:10.1136/bmj.e6231.
  9. 9.
    Patten SB, Williams JVA, Lavorato DH, Kassam A, Sabapathy CD. Pharmacoepidemiology of benzodiazepine and sedative-hypnotic use in a Canadian general population cohort during 12 years of follow-up. Can J Psychiatry. 2010;55:792–9.PubMedGoogle Scholar
  10. 10.
    Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23:19–34.CrossRefPubMedGoogle Scholar
  11. 11.
    Parr JM, Kavanagh DJ, Cahill L, Mitchell G, Young RM. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2008;104:13–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Oude Voshaar RC, Couvée JE, Van Balkom AJLM, Mulder PGH, Zitman FG. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. BJP. 2006;189:213–20.Google Scholar
  13. 13.
    Gould RL, Coulson MC, Patel N, Highton-Williamson E, Howard RJ. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. BJP. 2014;204:98–107.CrossRefGoogle Scholar
  14. 14.
    Wade A, Downie S. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig. Drugs. 2008;17:1567–72.CrossRefPubMedGoogle Scholar
  15. 15.
    Olde Rikkert MGM, Rigaud ASP. Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriat. 2001;34:491–7.Google Scholar
  16. 16.
    Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet. 1995;346:541–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Dagan Y, Zisapel N, Nof D, Laudon M, Atsmon J. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol. 1997;7:157–60.CrossRefPubMedGoogle Scholar
  18. 18.
    Garfinkel D, Laudon M, Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine treated elderly insomniacs. Arch Gerontol Geriatr. 1997;24:223–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CMJ, Brusco LI, Cardinali DP. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed middle-aged, and elderly patients. J Pineal Res. 2001;30:34–42.CrossRefPubMedGoogle Scholar
  20. 20.
    Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, (2009). Available from: http://www.cochrane-handbook.org. Accessed 24 Oct 2015.
  21. 21.
    Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.Google Scholar
  22. 22.
    Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin a new clinical approach. Arch Intern Med. 1999;159:2456–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Cardinali DP, Gvozdenovich E, Kaplan MR, Fainstein I, Shifts HA, Lloret SP, Albornoz L, Negri A. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuroendocrinol Lett. 2002;23:55–60.PubMedGoogle Scholar
  24. 24.
    Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2009;102:1947–53.CrossRefGoogle Scholar
  25. 25.
    Vissers FHJA, Knipschild PG, Crebolder HFJM. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci. 2007;29:641–6.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Garzon C, Guerrero JM, Aramburu O, Guzman T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res. 2009;21:38–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Lahteenmaki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä S. Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. Br J Clin Pharmacol. 2013;77:975–85.PubMedCentralCrossRefGoogle Scholar
  28. 28.
    Baandrup L, Lindschou J, Winkel P, Gluud C, Glenthoj BY. Prolonged release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo-controlled, blinded trial. World J Biol Psychiatry. 2015. doi:10.3109/15622975.2015.1048725.
  29. 29.
    Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F. A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2001;251:117–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Oude Voshaar RC, van Balkomb AJLM, Zitmanc FG. Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study. Eur Neuropsychopharmacol. 2004;14:301–6.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Angela Wright
    • 1
  • Jacqueline Diebold
    • 2
  • Jaskiran Otal
    • 2
  • Carly Stoneman
    • 1
  • Jonathan Wong
    • 2
  • Christine Wallace
    • 1
  • Mark Duffett
    • 3
  1. 1.St. Joseph’s Healthcare HamiltonHamiltonCanada
  2. 2.Hamilton Health SciencesHamiltonCanada
  3. 3.Departments of Pediatrics and Clinical Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada

Personalised recommendations